Compare KELYA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | AUTL |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.6M | 368.6M |
| IPO Year | N/A | 2018 |
| Metric | KELYA | AUTL |
|---|---|---|
| Price | $8.83 | $1.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.00 | $8.33 |
| AVG Volume (30 Days) | 557.0K | ★ 3.9M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,392,800,000.00 | $51,128,000.00 |
| Revenue This Year | $0.72 | $658.11 |
| Revenue Next Year | N/A | $91.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.46 | ★ 406.67 |
| 52 Week Low | $7.98 | $1.11 |
| 52 Week High | $15.11 | $2.80 |
| Indicator | KELYA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 60.25 |
| Support Level | $8.88 | $1.56 |
| Resistance Level | $9.28 | $1.69 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 46.86 | 89.92 |
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.